Defence Completes 2nd Tranche of Financing

Defence Completes 2nd Tranche of Financing

Vancouver, BC, Canada, March 22nd, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2nd...
Defence Completes 2nd Tranche of Financing

Defence Financing

Vancouver, C.-B., Canada, 19 janvier 2024 – Defence Therapeutics Inc. (« Defence » ou la « Société »), (CSE : DTC, OTCQB : DTCFF, FSE : DTC), l’une des principales entreprises de biotechnologie canadiennes œuvrant dans le domaine de l’immuno-oncologie annonce, suite à...
Defence Completes 2nd Tranche of Financing

Defence Financing

Vancouver, BC, Canada, January 19th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news...
Defence’s Accutox® Impairs Lung Cancer Growth

Defence’s Accutox® Impairs Lung Cancer Growth

Vancouver, BC, Canada, January 10th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it...